---
title: 'A new module in the drug development process: preclinical multi-center randomized
  controlled trial of R-ketamine on alcohol relapse'
date: '2025-02-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40021941/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250301170926&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'The drug development process in psychiatry faces significant challenges
  due to low reproducibility rates in animal testing, which often leads to translation
  failures. To address this issue, we introduce a new approach in psychiatric drug
  development: a preclinical randomized controlled trial (preRCT). To demonstrate
  its potential utility, we conducted a multi-center preRCT using the alcohol deprivation
  effect (ADE) model to assess the impact of ketamine and R-ketamine on alcohol relapse
  ...'
disable_comments: true
---
The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol deprivation effect (ADE) model to assess the impact of ketamine and R-ketamine on alcohol relapse ...